The global bacteriophage therapy market size was $42.1 mn in 2021 and is set to increase to about $60.71 mn by 2030 with a CAGR of 4.5% between 2022 and 2030.
Bacteriophage Therapy Market
The global bacteriophage therapy market was evaluated at $42.1 million in 2021 and is slated to hit $60.71 million by the end of 2030. The market report is an indispensable guide on growth factors, challenges, restraints, and opportunities in the global marketplace. The report covers the geographical market along with a comprehensive competitive landscape analysis. Additionally, the report explores the investor and stakeholder space to help companies make data-driven decisions.
As per NIH researchers, there is a rise in incidences of resistance of microbes to antibiotics and this has prompted new research in other domains such as bacteriophage therapy. For instance, in 2017, the WHO listed nearly 12 bacteria and classified them into three categories, namely, high, critical, and medium based on their resistance to available medicines and treatments. Moreover, the rate of resistance of microbes to antibiotics exceeds the proportion of antibiotic development and discovery. This has evolved as a new challenge to public health across the globe.
According to NCBI, nearly 10 million persons can die each year as a result of antimicrobial resistance by 2050. Moreover, this highlights the major concerns for the healthcare sector as it faces challenges in discovering new treatments for multi-drug resistant bacterial infections. For the record, natural predators of bacterial pathogens are bacteriophages. In addition, bacteriophages have proved to be effective modes of treatment and antibacterial therapeutic agents against MDR pathogens such as Pseudomonas aeruginosa, Enterobacteriaceae, and Acinetobacter baumannii.
Researchers are focusing on clinical studies on bacteriophage therapy to determine its effectiveness in treating the disease. Reportedly, bacteriophage therapy makes use of lytic phages to destroy their respective bacterial hosts without affecting healthy human cells along with minimizing the impact on commensal bacteria caused due to consumption of antibiotics.
COVID-19 Impact Analysis
Outbreak of COVID-19 pandemic has favorably influenced the demand for bacteriophage therapy across the globe. For the record, nearly 8% of COVID-19 patients develop secondary bacterial infections. However, 75% of these patients are administered antibiotics as prophylactic mode of treatment. Nevertheless, researchers have found that over-usage of antibiotics increase the probability of anti-microbial resistance and hinders the recovery of the patient. Moreover, clinical studies have found that bacteriophage therapy is an effective treatment alternative for COVID-19 patients over antibiotics as it possesses anti-inflammatory features and can effectively target the COVID-19 virus.
Massive application of bacteria for removing biofilms to boost the global bacteriophage therapy industry expansion
Surge in use of bacteria as therapeutic agents for treating bacterial infection to boost the global bacteriophage therapy market trends. Less toxicity and ease of production make bacteriophage a more preferable mode of treatment for bacterial infection. Furthermore, bacteriophages are used as biocontrol agents and find a slew of applications in microbial source tracking and fecal indicators. This, in turn, will prompt the expansion of the global bacteriophage therapy market. As per NIH researchers, bacteriophage suspensions when administered or delivered to patients via topical application and systemic administration in injection or oral form can treat staphylococcal infections of eyes, skin, and bones. Reportedly, these suspensions can also treat dysentery, typhoid, and cholera.
Furthermore, bacteriophages are also used in removing biofilm produced by bacteria such as P. aeruginosa & S. aureus. Moreover, biofilms are used by pathogenic bacteria for evading the immune system of a patient along with increasing resistance to the antibiotic. Recently, AmpliPhi Biosciences Corporation, a U.S.-based biotechnology company, launched a clinical trial on P. aeruginosa infections in cystic fibrosis chronic rhinosinusitis patients. As per the outcomes derived from the clinical trials, it was established that bacteriophages could successfully remove biofilms of P. aeruginosa in patients.
Effectiveness of bacteriophage treatment against antibiotic-resisting microbes and pathogens to generate new growth opportunities for the global market
Anti-biofilm activity and high specificity of bacteriophage have created huge growth avenues for the global bacteriophage therapy industry. Apart from this, bacteriophage therapy is effective against both antibiotic-sensitive pathogens as well as antibiotic-resisting microbes. Reportedly, bacteriophage reverses antibiotic resistance along with restoring susceptibility to antibiotics in Pseudomonas aeruginosa. Such beneficial features of bacteriophage are likely to open new vistas of growth for the global bacteriophage therapy market in the years to come. As per clinical studies conducted by NIH researchers, it was found that bacteriophage therapy was effective against bloodstream infections such as sepsis, bacteremia, and pneumonia. Such successful studies are likely to generate new facades of growth for the global industry.
High costs of bacteriophage therapy can prove impediment to the growth of the global market
Easy availability of substitute treatments for anti-microbial-resistant infections has created hurdles in the growth path of the bacteriophage therapy market. Apart from this, the huge costs of bacteriophage treatment have posed a bigger threat to the expansion of the global market. In addition to this, emerging and underdeveloped countries create more revenue from investments in antibiotics in comparison to bacteriophage, thereby hindering the growth of the global market.
Low raw material supply for manufacturing drugs due to irregular transportation has proved to be a major challenge for growth of the global market
Bacteriophage therapy is facing one of the biggest challenges in terms of legislation governing the use of bacteriophage treatment and government policies pertaining to its medical use. In addition, key challenges to the expansion of the global bacteriophage therapy industry include low raw material supply for producing medicines owing to irregularities in transport activities.
The global bacteriophage therapy market is divided into product, route of administration, application, and region.
Based on product, the global bacteriophage therapy industry is segmented into phage probiotics and phage therapeutic segments. Moreover, the phage probiotics segment is set to exhibit lucrative growth during the forecast timeframe and accounted for nearly 95% of the global market share in 2021. The segmental growth can be credited to the ability of phage probiotics in increasing the proliferation of good bacteria along with enhancing gut flora diversity. Apart from this, phage probiotics also promote healthy living among individuals who consume it, thereby leading to massive product demand.
On basis of route of administration, the global bacteriophage therapy industry is segmented into oral and topical segments. Moreover, the oral segment led the global bacteriophage therapy market share in 2021 and is expected to lead it even over the projected timeline. The segmental expansion can be owing to its non-invasive, self-administrable, and cost-efficient features. Apart from this, oral route of administration helps in decreasing the inflammation of gums.
In terms of application, the global bacteriophage therapy market is divided into wound prophylaxis, skin infection treatment, respiratory infections treatment, gastroenterology, and urogenital infection treatment segments. Moreover, the gastroenterology segment, which dominated the growth of the global market in 2021, is predicted to sketch a profitable road map for the global bacteriophage therapy industry in the coming years. The growth of the segment during 2022-2030 is due to the humungous use of bacteriophage as food supplements for improving the gut health of individuals.
|Report Attributes||Report Details|
|Report Name||Bacteriophage Therapy Market Research Report|
|Market Size in 2021||USD 42.1 Million|
|Market Forecast in 2030||USD 60.71 Million|
|Compound Annual Growth Rate||CAGR of 4.5%|
|Number of Pages||282|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Key Companies Covered||PhagePro, Inc., TechnoPhage SA, Eligo Bioscience SA, Armata Pharmaceuticals, Inc., ContraFect Corporation, Eliava Biopreparations Ltd., Fixed-phage Ltd., Pherecydes Pharma, BiomX Ltd., Adaptive Phage Therapeutics, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Phi Therapeutics, Locus Biosciences, Inc., Micreos BV, Intodeworld, Inc., Phagomed Biopharma GmbH., Enbiotix, Inc., and OPTIPHARM Co., Ltd.|
|Segments Covered||By Product, By Route of Administration, By Application And By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)|
|Countries Covered||North America: U.S and Canada
Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
Latin America: Brazil, Argentina, Chile
The Middle East And Africa: South Africa, GCC, Rest of MEA
|Historical Year||2016 to 2020|
|Forecast Year||2022 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America To Establish Global Market Domination Over 2022-2030
In terms of region, the global bacteriophage therapy industry is sectored into the Asia-Pacific, North America, Latin America, Europe, and the Middle East & Africa. The North American region is predicted to establish dominant status in the global market in the next eight years. The regional market surge over the forecast timeline can be due to a rise in antibiotic resistance witnessed among the patients who were affected by viral infections such as COVID-19 and other bacterial infections in the countries such as the U.S. Apart from this, there is an escalating demand for a more effective mode of treatment over antibiotics in the countries such as the U.S and Canada.
Furthermore, the Asia-Pacific region is anticipated to be the fastest-growing bacteriophage therapy market during the assessment period. The regional market growth can be credited to the presence of strong healthcare infrastructure facilities in countries such as India and Japan and favorable government policies towards bacteriophage therapy for treating patients affected due to bacterial infections.
The global bacteriophage therapy market is led by participants such as:
By Route of Administration
The global bacteriophage therapy market is projected to expand over 2022-2030 owing to a low toxicity and ease of production of bacteriophage which makes it a more preferrable mode of treatment for bacterial infection. Furthermore, bacteriophages are used as biocontrol agents and find slew of applications in microbial source tracking and fecal indicators.
According to study, the global bacteriophage therapy market size was $42.1 million in 2021 and is projected to reach $60.71 million by the end of 2030 with a compound annual growth rate (CAGR) of roughly 4.5% between 2022 and 2030.
The global bacteriophage therapy market is anticipated to be dominated by the North American region in the coming years owing to the rise in antibiotic resistance witnessed among patients who were affected by viral infections such as COVID-19 and other bacterial infections in the countries such as the U.S.
The global bacteriophage therapy market is led by players like PhagePro, Inc., TechnoPhage SA, Eligo Bioscience SA, Armata Pharmaceuticals, Inc., ContraFect Corporation, Eliava Biopreparations Ltd., Fixed-phage Ltd., Pherecydes Pharma, BiomX Ltd., Adaptive Phage Therapeutics, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Phi Therapeutics, Locus Biosciences, Inc., Micreos BV, Intodeworld, Inc., Phagomed Biopharma GmbH., Enbiotix, Inc., and OPTIPHARM Co., Ltd.